Special to Ophthalmology Times®
By Dr Yasmine M. El Sayed
From timolol to rho kinase inhibitors, glaucoma medications for primary open-angle glaucoma (POAG) have steadily progressed for decades.
Intravitreal injections used to treat a variety of ocular diseases may themselves contribute to progressive visual loss with chronic administration over years, according to researchers.
A fixed-dose tafluprost and timolol combination eye drop led to significant reductions in intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) and ocular hypertension (OHT) in a safety a
This article was reviewed by Felipe Medeiros, MD, PhD